Lung Cancer Trials

EMR 100070-004

EMR 100070-004 – A phase III open-label, multicenter trial of MSB0010718C versus Docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet.

What type of cancer? What stage?
1. 2nd line lung has opened
Who is eligible?

How will I be treated?
1. MSB0010718C-PDL1-Avelumab

SWOG 1400

SWOG 1400 – Phase II/III biomarker-driven master protocol for second line therapy of squamous cell lung cancer.

What type of cancer? What stage?
1. Lung cancer.
Who is eligible?
1. Patients who need 2nd line therapy of squamous cell lung cancer.
How will I be treated?
1. Patients will have therapies directed by tumor genetics.

E4512

E4512 – A phase III double-blinded trial for surgically early stage non-small cell lung cancer: crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein.

What type of cancer? What stage?
1. Lung cancer, surgically removed.
Who is eligible?
1. Patients who have an ALK mutation.
How will I be treated?
1. Patients may get Crizonitib (a drug approved for ALK+ lung cancer).

A081105

A081105 – Randomized double blind placebo controlled study of Erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small

What type of cancer? What stage?
1. Lung cancer.
Who is eligible?
1. EGFR mutant non-small cell lung cancer.
How will I be treated?
1. Erlotinib (anti-body based biologic).

A151216

A151216 – Genetic testing for patients with resectable or resected lung cancer: adjuvant lung cancer enrichment marker identification and sequencing trial (alchemist).

What type of cancer? What stage?
1. Lung cancer.
Who is eligible?
1. Patients whose disease is resected (surgically removed).
How will I be treated?
1. Genetic testing will be incorporated to learn more about tumor biology.

For physicians: more information about this specific trial at clinicaltrials.gov.